Mydrane - Drug Insight and Market Forecast - 2030

Overview
“Mydrane - Drug Insight and Market Forecast - 2030” report by the publisher outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Mydrane in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Drug Summary

Mydrane is an intracameral (IC) injection containing tropicamide 0.2 mg/ml (0.02%), phenylephrine 3.1 mg/ml (0.31%) and lidocaine 10 mg/ml (1%). Mydrane is indicated for cataract surgery to obtain mydriasis and intraocular anaesthesia during the procedure, offering an alternative method of mydriasis without the need for pre-operative mydriatic drops. The two mydriatics provide a rapid, stable mydriasis for the duration of the cataract surgery. It delivers speed, stability and comfort during the cataract surgery procedure. It is marketed by Thea Pharmaceuticals.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug marketed details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Mydrane.
• The report contains historical and forecasted sales for Mydrane till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
• The report also features the SWOT analysis with analyst insights and key findings of Mydrane.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Mydrane Analytical Perspective

In-depth Mydrane Market Assessment

This report provides a detailed market assessment of Mydrane in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

Mydrane Clinical Assessment

The report provides the clinical trials information of Mydrane covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Mydrane is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Mydrane dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other approved products for the disease are giving market competition to Mydrane and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Mydrane.
• This in-depth analysis of the sales data of Mydrane from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Mydrane in the market.

Key Questions Answered

• What is the prescribed dosage and strengths of Mydrane are available in the market?
• What are the common adverse reactions or side effects of Mydrane?
• What is the product type, route of administration and mechanism of action of Mydrane?
• What are the chemical specifications of Mydrane?
• How are the clinical trials diversified on the basis of the trial status?
• What is the history of Mydrane, and what is its future?
• What are the marketed details of Mydrane in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• How many patents have been granted to Mydrane and when these patents will get expire?
• What are the pros (benefits) and cons (disadvantages) of Mydrane?
• In which countries Mydrane got approval and when it gets launched?
• What are the clinical trials are currently ongoing for Mydrane?
• How the safety and efficacy results determined the approval of Mydrane?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Mydrane development?
• What are the key designations that have been granted to Mydrane?
• What is the historical and forecasted market scenario of Mydrane?
• How is the market trend of Mydrane is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
• What are the other approved products available and how these are giving competition to Mydrane?
• Which are the late-stage emerging therapies under development for the treatment of the indicated condition?